Briefing
LBA1 Dynamic circulating tumor DNA methylation monitoring guiding postoperative surveillance in non-metastatic colorectal cancer: Interim analysis of FIND trial
Cumulative recurrence rates did not differ (P=0.671 ITT). ctDNA-guided surveillance increased the proportion of recurrent patients who received curative-intent therapy (50.0% vs 22.6%; relative risk 2.214, 95% CI 1.060-4.780; P=0.034), the trial's primary endpoint. This is an interim analysis.
- Design: LBA
- n: 728 randomized (363 ctDNA-guided, 365 standard); interim, median follow-up 12 months
- Assay: single-tube methylation-specific quantitative PCR (mqMSP) targeting 10 methylation markers (stated detection to 0.01% allelic fraction)